Nuvectis Pharma (NVCT) Corporate presentation summary

Precision medicine strategy and pipeline

• Focus on developing targeted therapies for serious oncology conditions with unmet needs.

• Lead asset NXP900 is a novel, highly selective YES1/SRC kinase inhibitor discovered at the University of Edinburgh.

• Phase 1a dose escalation and drug-drug interaction (DDI) studies completed; Phase 1b program is ongoing with both monotherapy and combination arms.

• Potential indications include biomarker-selected advanced solid tumors and ALK/EGFR-mutated NSCLC.

• Management team has a strong track record with three approved drugs in four indications in the US and EU.

NXP900 clinical and preclinical data

• NXP900 demonstrates complete inhibition of YES1/SRC pathways, differentiating it from other multi-kinase inhibitors.

• Phase 1a showed robust pharmacodynamic response with ~90% SRC inhibition at doses ≥150 mg/day and an acceptable safety profile.

• Most common adverse events were diarrhea and fatigue (both 45%), with no dose-limiting toxicity identified.

• DDI study supports combination strategies, showing NXP900 is a weak inhibitor of CYP3A and CYP2B6, with no serious adverse events.

• Preclinical models show potent activity in lung, esophageal, and head and neck cancers with YES1 amplification or Hippo pathway mutations.

Phase 1b program and combination opportunities

• Phase 1b includes monotherapy cohorts for NSCLC, renal cancer, mesothelioma, and other solid tumors with specific genetic alterations.

• Combination cohorts target NSCLC patients with acquired resistance to EGFR or ALK inhibitors.

• Preclinical data show NXP900 reverses resistance to osimertinib and synergizes with lorlatinib in resistant cell lines.

• YES1 and SRC implicated in resistance mechanisms, supporting rationale for combination strategies.